Long term outcome of liver transplantation for viral hepatitis: is there a need to re-evaluate patient selection?

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT) Lancet (1998) 9.78

Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology (1997) 5.53

Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med (1993) 4.43

Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med (1996) 4.10

Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet (1997) 3.11

Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology (1996) 2.99

Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology (1996) 2.94

Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation. Gastroenterology (1995) 2.00

Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology (1998) 1.95

Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet (1996) 1.78

Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation. Hepatology (1997) 1.74

Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology (1991) 1.65

Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology (1998) 1.48

Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation. Hepatology (1996) 1.42

The influence of hepatitis C virus genotypes on the outcome of liver transplantation. Liver Transpl Surg (1998) 1.42

The course of hepatitis C virus infection after liver transplantation. Hepatology (1994) 1.38

Severity of liver disease in liver transplantation recipients with hepatitis C virus infection: relationship to genotype and level of viremia. Hepatology (1996) 1.19

High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation. J Hepatol (1999) 1.17

Histological and clinical outcome after liver transplantation for hepatitis C. Hepatology (1997) 1.10

The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation. Hepatology (1998) 1.03

Liver transplantation in HBs antigen (HBsAg) carriers. Prevention of hepatitis B virus (HBV) recurrence by passive immunization. J Hepatol (1991) 0.97

Retransplantation for recurrent hepatitis C. Liver Transpl Surg (1997) 0.90

Recurrent hepatitis B in liver allografts: a distinctive form of rapidly developing cirrhosis. Histopathology (1993) 0.81

Liver transplantation for hepatitis B: the con aspect. Liver Transpl Surg (1995) 0.78